Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Although FDA did not approve the biosimilar for pediatric ulcerative colitis, Inflectra labeling states that a pediatric assessment demonstrates it is 'safe and effective in another pediatric indication.'
You may also be interested in...
US Biosimilar Sponsors Seek Off-The-Record Discussions
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.
Biosimilar Sponsors Want Off-The-Record Labeling Discussions With US FDA
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions written record; negotiations for BsUFA III may be opportunity to create such a process.
Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.